Leaves of grass

Half a dozen key posters to watch out for in early stage oncology at SITC22

November 9, 2022

SITC Preview 2 – a look at novel and emerging IO targets

Five areas of early stage IO developments to watch out for

October 14, 2022

Dawn of new directions for protein and glue degraders

Where is the TPD field likely headed with next generation approaches?

October 4, 2022

Fishing for Gems from the Poster Halls Part 1

Bispecifics come and bispecifics go as companies seek to find a balance

September 29, 2022

Analysis of the CodeBreak 200 trial in lung cancer

An in-depth look at some of the issues impacting Amgen's pivotal trial and what it means for their competitors

September 14, 2022

ESMO22 Developmental Therapeutics Preview on Immunotherapies

In our latest ESMO conference preview it’s time to pick some early stage immunotherapy highlights…

August 31, 2022

New controversies in GI malignancies

What to watch out for in colorectal cancer, cholangiocarcinoma and hepatocellular carcinoma

August 24, 2022

New directions in small cell lung cancer

A look at promising new approaches in SCLC

August 12, 2022

A critical review of five different targeted therapy approaches at ASCO

Where five different targeted therapies are put through their paces

June 13, 2022

ASCO22 Highlights from Day 1

When cell therapies and targeted therapies collide

June 4, 2022

Five key areas to watch out for at ASCO22

Five key areas to watch out for at ASCO22

June 1, 2022

A journey that never ends

Can NK cells help checkpoint blockade work more effectively?

April 27, 2022

An inconvenient truth

Looking beyond the hype from a broader perspective

April 18, 2022

Off the beaten track in the bispecific landscape

Everything you needed to know about bispecifics at AACR22 and more!

March 31, 2022

5 important topics to watch out for at AACR22 on bispecifics

5 areas to watch out for on the bispecific antibody front

March 25, 2022

Challenges and opportunities with two different onco modalities

The latest on bispecifics and protein degraders

March 10, 2022

Aspiring to new heights – and new modalities

Can a different twist on modality make a real difference and go beyond what we already have?

March 4, 2022

What to watch out for on the CAR-T cell therapy front

Several controversies abound in the CAR-T cell niche this year, plus what's coming next?

December 7, 2021

Can bispecifics succeed where ADCs have failed?

Finessing oncology targets can be both tricky and challenging. Does changing the modality help?

November 23, 2021

Lessons learned from SITC – Part 1

Sometimes we learn more from failure than we do from success

November 16, 2021

An immunotherapy for the long run – or tail

With SITC fast coming up this week, immunotherapies in all sorts of shapes and guises are very much…

November 8, 2021

Scores on the doors in the TIGIT niche

Update on the various runners and riders in the TIGIT niche

November 3, 2021
Washington DC in Fall

SITC21 – What to Watch out for

SITC 2021 Preview

October 22, 2021

New developments on the lymphoma horizon

Key learnings and highlights from the recent AACR DLBCL specialist meeting

October 5, 2021

When things fall apart

One of the things that struck me at this year’s ESMO conference was the sheer variety and richness…

September 29, 2021

Storm Clouds or Sunny Skies? What’s on the horizon for Early Stage IO Development Data at ESMO21

A hard look at some IO agents in early development at ESMO21

September 18, 2021

WCLC21 Preview of key data to watch out for

What's hot at WCLC21?

August 19, 2021

A novel target to explore in prostate cancer

Is it a marker or a target? Actually, what is the target - and why does it matter?

August 5, 2021

Novel anti-cancer agents to watch out for

A look at five novel anti-cancer agents in early R&D pipelines and what we can learn from their experiences

April 30, 2020

Gritting it out

What are Gritstone up to behind the scenes and where are they headed in the near-term?

July 20, 2021

New developments on the T cell engager front

Update on the T cell engager niche with an emerging agent of interest

July 8, 2021

Advent of a new era in advanced prostate cancer treatment

A look at the first anti-cancer therapy with a radiopharmaceutical in advanced prostate cancer

June 3, 2021

Dancing with proteins at the Masquerade

Who's going to the masquerade ball and how might they fare in the future?

June 1, 2021

The Future of Cell and Gene Therapies

13 ways in which CAR based or gene therapies can improve on current approaches to cell therapies

April 22, 2021

Highlights and commentary on key AACR21 data presentations

13 talks at AACR21 caught our attention - which ones intrigued or dismayed - and why?

April 13, 2021

AACR21 Preview 8 – The growing bispecific niche

A rock around the bispecific clock highlighting key presentations coming at the AACR 2021 virtual meeting

April 8, 2021

Novel combination strategies to enhance KRAS inhibitors

Combinations will be the future for KRAS inhibitors but which ones and why? Includes some new ideas!

March 16, 2021

Emerging developments and trends in advanced lung cancer

Gems from the WCLC20 poster hall which may make an impact

February 9, 2021

A look at the exon 20 landscape in lung cancer

A look at the exon 20 insertion landscape - all to play for!

February 4, 2021

Parallel lines: opportunities and challenges in GI cancers

Important developments on the GI cancer front to watch out for

January 19, 2021

Strategic direction and future impacts in multiple myeloma

A rock around the myeloma clock through the eyes of a KOL - what stood out and what did not?

January 14, 2021

How bispecifics will make an impact in myeloma

Beyond CAR-T cell therapy there are novel bispecifics coming along so where and how will they fit in?

January 13, 2021

An exciting pipeline of early stage oncology agents from BMS

A critical look at the early stage BMS oncology pipeline

January 11, 2021

Future of NK Cell Therapy – Part 2

Commentary on engineered NK cells, including CAR-NK and memory-like NK cells

January 6, 2021

Future of NK Cell Therapy – Part 1

Expert commentary on new data relating to NK cell therapies - are they ready for prime time yet or not?

January 5, 2021

A critical review of bispecific antibodies at ASH20

What caught our attention on novel bispecific antibodies at ASH20?

December 7, 2020

ASH20 Preview of progress with bispecific antibodies

Updated look at the bispecific landscape in early clinical development

November 9, 2020

Potential new targets and biomarkers for immunotherapy

How we can learn more from failure in clinical trials so we can improve outcomes further with emerging agents in early development

October 20, 2020

A contrarian view of key cancer trial results

Winners, losers and risers... who goes where in the final analysis?

October 8, 2020

ESMO20 Preview 4 – Targeted therapies to watch out for

What to watch out for this weekend in targeted therapies and early stage new product development

September 17, 2020

ESMO20 Preview 3 Developmental Therapeutics – IO therapies

Five IO areas in early stage development to watch out for at ESMO20

September 15, 2020

ESMO20 Preview 2 – New Targets, New Opportunities

Can we predict the future cancer drug combinations from emerging new targets?

September 10, 2020

Making a splash in the competitive CAR-T space

If we were to tackle CAR T cell therapy design differently, how would we go about doing it?

July 13, 2020

New developments in CAR-T cell therapies including controversial ones

The ups and downs of CAR-T cell therapy development continues apace

July 8, 2020

Are gamma delta T cells ready yet for prime time?

Update on the Gamma Delta T cell niche - what's new, what's up, and what's down?

July 1, 2020

Looking through the window at some novel new product development concepts in oncology

A look at some novel and promising approaches in early oncology new product development

June 24, 2020

Who is winning the CD20xCD3 Bispecific Race to Market?

An update on the CD20 x CD3 bispecific with expert commentary on data at ASCO EHA.

June 15, 2020

AACR20 – Ten New Directions in Early Cancer Drug Development

Ten intriguing novel agents in early development to watch out for

April 23, 2020

Unlocking novel IO targets and anti-cancer agents in early development

When T cells stop working how can we get innate immune cells like NK cells to take up the slack and help track down tumours?

March 24, 2020

The dog that didn’t bark

A look at what happened from the DREAMM1 to DREAMM2 trials exploring the BCMA ADC belantamab mafadotin in refractory multiple myeloma and why GSK have a challenge ahead

December 17, 2019

In Plain Sight

A look at some of the highly ranked clinical data presented over the weekend in Orlando

December 9, 2019

ASH19 10 innovative approaches in Hematologic Malignancies

Some hidden gems and under the radar abstracts that may appeal to the off-Broadway crowd at ASH19

November 19, 2019
National Harbor Maryland

Key Highlights from Day 1 at SITC19

If we want to improve on the current results with IO therapies then we need to go to basics and understand the biology of each disease subset in the context of what we've learned so far

November 8, 2019

Targeting NRG1 Gene Fusions

What did we learn at #Targets19 about targeting NRG1 gene fusions with MCLA-128?

October 27, 2019

Insights on the Jounce-Celgene collaboration and ICOS agonism

Thoughts and commentary on the Jounce-Celgene collaboration update and the emerging ICOS landscape

July 24, 2019

A look at Amgen’s early oncology pipeline

Amgen have a large early phase 1 oncology pipeline including bispecifics, BiTEs, a CAR and small molecules. What can we learn from recent data presented?

July 18, 2019

Will innate bispecifics make a difference in hematologic malignancies and solid tumours?

What can we learn from the recent data presented on Affimed's innate bispecific platform? A candid conversation with CEO, Dr Adi Hoess

July 11, 2019

The Next Wave of IO with Dr Dan Chen

We saw a number of challenges emerge with immune agonists as antibodies and now companies are experimenting with them in bispecifics - what needs to be considered to make them work? What will the next wave of IO look like?

July 9, 2019

How failure allows us to continually innovate

How the design of different cancer approaches can affect clinical performance

June 24, 2019

Key highlights on lymphomas from iCML

Round-up and analysis of key lymphoma data at iCML 2019

June 20, 2019

Insights from CIMT in Mainz Part 2

Highlights (and lowlights) from Day 2 of immunotherapy presentations at CIMT 2019 in Mainz.

May 23, 2019

What to watch out for in Bispecifics at ASCO19

A review of 7 different targets and 18 different compounds in the maturing and highly competitive bispecific niche.

May 28, 2019

Going beyond BCMA as a target in multiple myeloma

Is there a better way to target myeloma than with BCMA alone? Data suggests there's plenty of room for improvement.

April 22, 2019

Defense is the Best Attack – Part 1

Update on T cell bispecifics and other key topics in early stage IO development

March 12, 2019

How do we improve on 1st Generation T cell bispecifics?

An upcoming small biotech focused on IO targets with their novel platform approach

January 28, 2019

The Yin and Yang of biomarkers in cancer research

Some examples of potentially useful biomarker inclusion in early oncology trials

January 22, 2019

Insights from the ASCO GI19 conference

What to watch out for at the ASCO GI19 conference in San Francisco

January 17, 2019

A tale of two cities – a look at two small immunotherapy biotechs

Going beyond anti-PD1 checkpoint blockade is important if we want to help more people respond to cancer immunotherapy

January 14, 2019

The challenges of bispecifics

FDA slaps a partial clinical hold for unwanted side effects, now what?

December 11, 2018

ASH18 Highlights from Day 3

Review of a round dozen key abstracts at #ASH18, both scientific and clinical data is under the microscope!

December 3, 2018

ASH18 Highlights from Day 2

We offer 13 key highlights from day 2 of ASH18, including some surprises.

December 2, 2018

ASH18 Preview 3 – BCMA

From one BCMA directed CAR in 2015, we now have a very competitive niche in multiple myeloma. What's in store?

November 26, 2018

SITC18 Preview and IO curiosities

An extensive round-up of what to expect from SITC18 ahead of the abstract reveal

November 2, 2018

Learnings from IO combinations and where we’re headed

Lessons learned from recent failure and a look at where a few new developments might be coming from...

August 23, 2018

Preview of CICON18 – Part 1

Part 1 of our #CICON18 Previews - a look at 11 intriguing IO related studies

September 20, 2018

New Insights on BCMA BiTEs and CAR T cell therapies in Myeloma

Update on BCMA, SLAMF7 and other targets in multiple myeloma

September 11, 2018

Pathways to success with NK cell therapy

Will NK cell engagers have a positive impact on checkpoint therapy and other adaptive immunotherapies?

August 28, 2018

In a Prudential Light

Bringing together disparate notes on cytokines and how they can be useful as an immunotherapy partner.

June 19, 2018

A different take on targeting cancer

How do we drive more T cells into the tumour? Here's one company who are looking to do just that.

May 8, 2018

A look at an up and coming west coast biotech

A look at the pipeline of the up and coming Seattle biotech, Alpine Immune Sciences

January 22, 2018

The Future of Multiple Myeloma

A look at key pipeline developments in multiple myeloma through the lens of a global expert in the field

January 2, 2018

Update on CD123 and other viable targets in AML

With increasing evidence that CD123 is a suboptimal target in AML, what other approaches might be more useful to consider?

October 17, 2017

AACR18 Day 2 Highlights

A look at the Class of 2018 new products in development - a hit or miss?

April 16, 2018

Jumpstarting the immune system with synthetic immunity

Jumpstarting the immune system with a synthetic immunity approach - how can we do this?

August 2, 2017

A hidden gem at ASCO17

How can we boost the efficacy of checkpoint therapies? One way is to drive more activated T cells into the tumour.

August 1, 2017

A promising IO combo approach to watch out for

Overcoming resistance to monotherapy treatment with checkpoint blockade is crucial for success with IO combos. Here's one potential solution...

June 19, 2017
ASCO 2014 Chicago Contemplation

An up and coming area in early oncology R&D

A look at an up and coming niche in cancer research that may turn out to be useful in conjunction with checkpoint blockade

May 22, 2017

One Step Beyond

With so many new anti-cancer agents, including immunotherapies, emerging in company pipelines, this means that we could see the evolution of important therapy sequences... going beyond combinations.

July 5, 2016

Xencor and Novartis storm the hematologic bispecific market

The oncology bispecific market is heating up with J&J collaborating with Macrogenics and Novartis with Xencor. We discuss the skinny...

June 28, 2016

Beyond Blinatumomab – Update on Bispecific T cell Engagers

In this post I've taken a close look at one cancer immunotherapy approach with a lot of data at AACR - bispecific T cell engagers.

March 31, 2016

How do we boost the effectiveness of checkpoint inhibitors?

A primer on immunocytokines in cancer immunotherapy with a focus on Roche's CEA-IL2v as a example.

November 2, 2015

Top 10 #ASH17 abstracts to watch out for

The Mav's key oral abstracts to follow at #ASH17 -- warning this list includes quirky selections!

November 30, 2017

Next generation approaches to immuno-oncology – where next?

What's next in immuno-oncology: what are potential ways to tackle the patients who do not respond to checkpoint immunotherapy?

January 8, 2015